18 results about "Oxaliplatin" patented technology

This invention discloses a composite nanozyme that enhances the clinical efficacy of oxaliplatin, its preparation method, and its application. The composite nanozyme consists of indium ruthenium nanozyme and an iliximab embedding and anchoring layer. The indium ruthenium nanozyme consists of indium ruthenium nanoparticles and a carbon-nitrogen framework, with the indium ruthenium nanoparticles loaded on the surface and within the pores of the carbon-nitrogen framework. The iliximab embedding and anchoring layer consists of a dithiol polyethylene glycol coating layer and iliximab. Preparation method: ZIF-8 is prepared by co-precipitation of zinc salt methanol solution and 2-methylimidazole methanol solution, followed by calcination to obtain the carbon-nitrogen framework. The carbon-nitrogen framework dispersion is then stirred in an oil bath with indium nitrate solution and ruthenium trichloride solution to prepare a nanozyme precursor, followed by calcination to obtain indium ruthenium nanozyme. The indium ruthenium nanozyme is dispersed in a dithiol polyethylene glycol solution, and iliximab solution is added dropwise. The resulting solid product is then dried. This invention can solve problems such as strong drug tolerance, insufficient intracellular accumulation, and severe tumor immunosuppression in oxaliplatin treatment.

This invention discloses a composite nanodelivery system encapsulated in a fusion membrane, its preparation method, and its applications. The nanodelivery system comprises a Ti3C2 / TiO2 / CuInS2 composite material, oxaliplatin loaded thereon, and a fusion membrane encapsulating the outer layer; the fusion membrane is formed by the fusion of Fusobacterium nucleatum extravesicles and M1 macrophage membranes. This invention also discloses a method for preparing the nanodelivery system, including the steps of preparing the Ti3C2 / TiO2 / CuInS2 composite material, preparing the fusion membrane, loading oxaliplatin, and encapsulating it in the fusion membrane. The nanodelivery system prepared by this invention exhibits pH-responsive drug release characteristics, generating H2S in the tumor microenvironment and H2 under light irradiation, while also possessing photocatalytic activity. This invention combines chemotherapy, photoelectrocatalytic therapy, and the regulation of multiple active substances, and can be used to prepare drugs for treating malignant tumors of the digestive system.

The present application relates to the application of ocanin in the preparation of anti-tumor drugs, and the ocanin is used in the anti-tumor drugs alone or in combination with 5-fluorouracil, and the concentration of the ocanin used in the preparation of anti-intestinal cancer drugs is 20-500 uMol. It is found that the ocanin can inhibit the growth of intestinal cancer cells in vivo and in vitro, and the naked mice have good tolerance to the natural compound. The ocanin has better anti-intestinal cancer effect than other extracts of goldeneye and devil's needle, and has better anti-cancer effect and smaller toxicity than the current conventional intestinal cancer drug 5-fluorouracil. Therefore, the ocanin can be developed into a new anti-cancer drug.

This invention provides biomimetic nanopharmaceuticals for mitochondrial dysfunction, methods for producing the same, and applications. [Solution] The biomimetic nanodrug comprises an RGD-engineered exosome as a carrier, decalinium chloride modified on the surface of the carrier, and oxaliplatin encapsulated inside the carrier. The biomimetic nanodrug of the present invention (OXA@Exo-RD) protects cargoes that induce mitochondrial dysfunction in the blood circulation process, sequentially increasing the accumulation of mitochondria in the cargoes by targeting them. Cargo 1 (DQA) induces oxidative stress, triggering mitochondrial-mediated apoptosis and mitochondrial dysfunction, while cargo 2 (OXA) disrupts mitochondrial DNA and inhibits the initiation of DNA repair, thereby improving chemotherapy resistance. Both cargoes synergistically overcome CRC drug resistance and inhibit its migration.

The present application relates to the role of UCK1 in promoting the sensitization of colorectal cancer treatment. The present application discloses the key role of UCK1 in the treatment of colorectal cancer. Clinical samples show that the expression of UCK1 in tumor tissues is reduced, and its low expression is related to chemotherapy resistance and poor prognosis. Studies have shown that UCK1 enhances the efficacy of oxaliplatin (OXA) by regulating metabolic pathways, and promotes B cell activation, thereby recruiting CD8 + T cells, and strengthens anti-tumor immunity. UCK1 overexpression can significantly improve OXA sensitivity and produce a synergistic effect with anti-PD-1 therapy. The present application proposes a new strategy centered on activating UCK1, providing a theoretical basis and application prospect for improving the response of colorectal cancer chemotherapy and immunotherapy.

The application belongs to the field of new adjuvants and new dosage forms of pharmaceutical preparations, and particularly relates to a type I and type II immunogenic cell death inducer ion pairing engineered nanoassemblies as well as construction and application thereof. The nanoassemblies are composed of type I ICD inducers, type II ICD inducers, hydrophobic auxiliary counterions and amphiphilic lipid ion pairing. The type I ICD inducer is selected from mitoxantrone, doxorubicin, oxaliplatin or cyclophosphamide; the type II ICD inducer is selected from hypericin; and the hydrophobic auxiliary counterion is selected from cholesteryl sodium sulfate, cholic acid, deoxycholic acid, chenodeoxycholic acid, lithocholic acid, glycolcholic acid, taurocholic acid, glycochenodeoxycholic acid, taurochenodeoxycholic acid, deoxycholic acid lysine derivative, oleanolic acid and ursolic acid. The type I and type II ICD inducers are combined in the application, and have a synergistic tumor treatment effect.

This invention relates to the fields of microbiology and biomedicine, and particularly to a strain of *Lactobacillus brittlemi* SYSU-32 and its application in tumor treatment. This invention cultured and isolated a strain of *Lactobacillus brittlemi* (SYSU-32). Limosilactobacillus pontis SYSU-32 was deposited on September 15, 2025, at the China General Microbiological Culture Collection Center (CGMCC), with accession number CGMCC No. 35919. This strain can increase CD8+ in the tumor microenvironment. + Infiltration of T cells and cytotoxic T cells inhibits the progression of colorectal cancer. Furthermore, the combination of *Lactobacillus bridgedii* SYSU-32 with the chemotherapy drug oxaliplatin enhances the pro-apoptotic effect of oxaliplatin, further inhibiting tumor progression and metastasis.

The application discloses application of a Blautia in preparation of a drug for enhancing sensitivity of colorectal cancer to oxaliplatin, B-CM can significantly enhance OXa cytotoxicity on drug-resistant colorectal cancer cells, inhibit proliferation, clone formation, migration and invasion ability. Combination therapy can synergistically induce apoptosis, although the expression of MDR1 in drug-resistant cells is up-regulated, but the combination of B-CM and OXa can significantly reduce the mRNA and protein levels. In vivo experiments show that B-CM enhances the tumor inhibition effect of OXa, which is related to the reduction of the expression of Ki-67 and MDR1 in tumor tissues. Further, it can be shown that the soluble factor derived from Blautia can reverse the drug resistance of colorectal cancer to oxaliplatin by down-regulating MDR1 and inhibiting epithelial-mesenchymal transition. This shows that Blautia-derived metabolites are a promising new adjuvant strategy to overcome chemotherapy resistance of colorectal cancer.

Disclosed are method of treating a subject in need thereof comprising applying an alternating electric field, at a frequency for a period of time, to a target site of the subject in need thereof; and administering a combination of leucovorin calcium, fluorouracil, irinotecane hydrochloride, and oxaliplatin to the subject in need thereof. Disclosed are methods of reducing viability of cancer cells comprising applying an alternating electric field, at a frequency for a period of time, to a population of cancer cells; and contacting the population of cells with a combination of leucovorin calcium, fluorouracil, irinotecane hydrochloride, and oxaliplatin. Disclosed are methods of increasing apoptosis of cancer cells comprising applying an alternating electric field, at a frequency for a period of time, to a population of cancer cells; and contacting the population of cancer cells with a combination of leucovorin calcium, fluorouracil, irinotecane hydrochloride, and oxaliplatin. Disclosed are methods of reducing the number of cancer cells comprising applying an alternating electric field, at a frequency for a period of time, to a population of cancer cells; and contacting the population of cancer cells with a combination of leucovorin calcium, fluorouracil, irinotecane hydrochloride, and oxaliplatin.

This invention discloses the application of fruquintinib combined with PD-1 monoclonal antibody in maintenance therapy for HER-2 negative advanced gastric cancer / geoesophageal junction adenocarcinoma, belonging to the field of tumor treatment technology. This invention targets HER2-negative advanced gastric cancer or gastroesophageal junction adenocarcinoma, specifically patients who achieve disease control after 3 months of first-line induction therapy with PD-1 monoclonal antibody combined with oxaliplatin, followed by maintenance therapy with fruquintinib combined with PD-1 monoclonal antibody without chemotherapy. The maintenance therapy regimen provided by this invention improves patients' quality of life and prolongs overall survival while delaying disease progression, and has significant clinical implications.

This invention discloses the preparation of an oxaliplatin-containing targeted formulation and its application in the treatment of colorectal cancer, belonging to the field of pharmaceutical formulation technology. The formulation consists of an active ingredient and a coating carrier; the active ingredient is oxaliplatin and a compound extracted from reed rhizome (1' R ,2' S )-Eugenol-based glycerol 3'- O -β- D The formulation consists of a covalently coupled oxaliplatin-glucopyranoside formed via amide bonds, with a mass ratio of 1:1 to 1:2. The coating carrier is a chitosan-sodium alginate composite microsphere, with a mass ratio of its suspension to the covalently coupled sphere of 10:1 to 15:1. This structure forms a stable protective layer in the acidic environment of the stomach, preventing premature release of the active ingredient. The preparation method involves three steps: first, preparing the oxaliplatin covalently coupled sphere; second, preparing the chitosan-sodium alginate composite microsphere suspension; and finally, ultrasonically dispersing, centrifuging, washing, and freeze-drying the coupling sphere and microsphere suspension to obtain a formulation with a particle size of 100-500 nm. This formulation utilizes a natural polysaccharide carrier, exhibiting good biocompatibility, non-toxicity, and strong targeting. It protects the active ingredient, ensuring its smooth passage through the stomach to the colon for release, enhancing drug efficacy and reducing toxic side effects, thus demonstrating promising clinical application prospects.

Method for treating cancer in a patient consisting of administering a systemic chemotherapy regimen in combination with radioactively labeled particles, characterized in that both therapies, when introduced into the patient, have an enhanced anticancer effect.

The application belongs to the field of pharmaceutical chemistry, and particularly relates to an oxaliplatin prodrug and a preparation and application thereof. The structure of the oxaliplatin prodrug is specifically shown as formula (I). The oxaliplatin prodrug can be dissolved in physiological saline to form a nano preparation, which not only solves the instability problem of oxaliplatin in physiological saline, but also reduces the systemic toxicity of oxaliplatin, and achieves the effect of reducing toxicity and increasing efficiency. The oxaliplatin prodrug can be reduced in a reducing environment in tumor cells to release oxaliplatin to kill tumor cells, and achieve an antitumor effect superior to that of oxaliplatin. The synthesis method of the oxaliplatin prodrug and the preparation method of the nano preparation are simple and easy to implement, which are conducive to solving the poor stability problem of oxaliplatin in physiological saline, and are expected to realize clinical transformation.

The application provides a polylysine nanomaterial for oxaliplatin transmission and a preparation method thereof, and relates to the technical field of biopharmacy. The synthesis method has clear synthesis route and strong controllability. Through modular design, alkynyl hyaluronic acid, azide polylysine-vitamin E succinate and MMP enzyme sensitive peptide segment connector are prepared in sequence, and finally, click chemistry is used for efficient coupling. The product has clear structure, high purity and good batch reproducibility, and overcomes the problems of low coupling efficiency and many by-products in traditional methods. The prepared drug has the abilities of active targeting and double response drug release. The hyaluronic acid can specifically recognize the CD44 receptor highly expressed on the surface of tumor cells to realize active targeting. The MMP enzyme sensitive peptide segment can be cleaved by the overexpressed MMP-9 enzyme in the tumor microenvironment to realize enzyme response drug release. Meanwhile, the disulfide bond structure introduced in the carrier can be broken in the high concentration glutathione environment to realize reduction response drug release.

This invention discloses the application of hsa-miR-148b-5p in the preparation of chemotherapy drugs for treating malignant tumors and for enhancing chemotherapeutic efficacy, belonging to the field of biomedical technology. This invention is the first to demonstrate that hsa-miR-148b-5p can reverse the resistance of tumor cells to chemotherapy drugs. In vitro cell experiments show that hsa-miR-148b-5p mimic has a synergistic effect when used in combination with cisplatin or oxaliplatin, significantly enhancing the killing effect of chemotherapy drugs on tumor cells. In vivo PDX mouse models further validate that the combined use of hsa-miR-148b-5p mimic and cisplatin can synergistically inhibit tumor growth, with the tumor growth inhibition rate in the combined treatment group being significantly higher than that in the single-drug treatment group. This invention provides a new technical solution for overcoming chemotherapy resistance in malignant tumors and has significant clinical translational value.

The present invention relates to novel EGFR inhibitor-functionalized albumin-binding platinum compounds of formula (I), including in particular EGFR inhibitor-functionalized albumin-binding oxaliplatin and carboplatin derivatives, as well as their use in therapy, particularly for the treatment or prevention of cancer. (Formula (I))

This invention discloses a siRNA, shRNA, and lentiviral vector targeting and silencing hsa_circ_007800, and their applications. A siRNA targeting and silencing hsa_circ_007800 is provided, and the corresponding shRNA lentiviral expression vector and lentivirus are constructed. In vivo and in vitro experiments demonstrate that the above-mentioned specific siRNA or shRNA can effectively inhibit the expression of hsa_circ_0007800, thereby inhibiting the proliferation, colony formation, migration, and invasion of oxaliplatin-resistant colorectal cancer cells. It also significantly inhibits tumor growth and enhances the chemotherapeutic effect of oxaliplatin in a nude mouse subcutaneous xenograft model. The proposed interfering molecule targeting hsa_circ_0007800 and its lentiviral vector have significant clinical application value and promising prospects in the preparation of drugs for treating oxaliplatin-resistant colorectal cancer.

This application discloses the application of RECQL as a target in the preparation of products for the treatment and diagnosis of gastric cancer, belonging to the field of biomedical technology. Its key technical point lies in providing the application of RECQL as a target in the preparation of products for diagnosing the sensitivity of gastric cancer patients to oxaliplatin chemotherapy or for diagnosing the efficacy and prognosis of patients receiving oxaliplatin. This application, by detecting RECQL gene / protein expression, histone H1.2 binding status, and K637 site lactation level, can efficiently predict patient drug sensitivity, avoiding the toxic side effects and treatment delays of indiscriminate chemotherapy. Targeted methods such as downregulating RECQL activity, blocking related binding, or inhibiting lactation can effectively restore oxaliplatin-induced DNA damage, significantly reverse drug resistance, and improve chemotherapy efficacy. Simultaneously, the key target is clearly identified, facilitating new drug development, and the relevant effects have been verified through in vitro and in vivo experiments, inhibiting the proliferation of drug-resistant cells and reducing tumor volume, laying a solid foundation for clinical translation, and possessing both practical value and translational potential.